Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: February 25, 2026
Reporting Period: Single event date (February 25, 2026)
Business Overview: The registrant is a Delaware corporation focused on diagnostic technologies, specifically the CyPath® Lung diagnostic test. The company is classified as an emerging growth company.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
There are no financial material changes reported in this document. The material event reported is a strategic partnership announcement:
- New Study: Initiation of a study with Brooke Army Medical Center (BAMC).
- Objective: To validate the clinical utility of the CyPath® Lung diagnostic test.
- Methodology: Assessment of sputum samples obtained via tracheal and bronchial suctioning.
- Target Application: Early detection of lung cancer.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) detailing the new study but does not include forward-looking financial guidance or specific management commentary on future performance metrics within the text provided.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies. However, the success of the announced study is contingent upon clinical validation results, which are not yet available.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for specific study timelines and inclusion criteria.
- Confirm the current status of the CyPath® Lung diagnostic test regulatory approvals.
- Review recent 10-K or 10-Q filings for the most up-to-date financial position, as this 8-K contains no financial data.
- Monitor future filings for results or updates regarding the Brooke Army Medical Center study.